Olema Pharmaceuticals, Inc. (OLMA)
After hours:
| Previous Close | 7.87 |
| Open | 8.21 |
| Bid | 8.77 x 100 |
| Ask | 8.84 x 100 |
| Day's Range | 7.95 - 8.90 |
| 52 Week Range | 7.68 - 16.77 |
| Volume | |
| Avg. Volume | 475,062 |
| Market Cap | 503.075M |
| Beta (5Y Monthly) | 2.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.28 |
| Earnings Date | Nov 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.86 |
GlobeNewswireOlema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) New clinical data for palazestrant (OP-1250) in combination with ribociclib to be presented at the San Antonio Breast Cancer Symposium (SABCS) in DecemberIND submission for OP-3136 expected before year end; clinical study to initiate early 2025Cash, c
- GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that its management team will participate in the following upcoming investor conferences: Jefferies London Healthcare ConferenceDate: Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET)Location: Lon
